Understanding Basic Stock Data: Vertex Pharmaceuticals Incorporated (VRTX)

In the past 52-week period, shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) have moved within the range of $71.46 to $167.85. On the stock’s most recent trading day, the company’s shares ended the regular session at $138.79, which is 17.31% lower than its 52-week high.

Vertex Pharmaceuticals Incorporated (VRTX) has demonstrated a 20-day simple moving average (SMA) of -5.66%, and a 50-day SMA of -7.20%. This public company’s current market capitalization stands at $34.97 billion.

Analyzing Consensus Estimates, Sales Revenue and Net Income

Checking the amount of enthusiasm that Wall Street analysts hold for a particular stock is crucial when thinking about entering a position. According to the latest data, the consensus recommendation for Vertex Pharmaceuticals Incorporated (VRTX) is Outperform.

Public companies normally post earnings and revenue results that fall somewhat above or below the average Wall Street estimate. In the most recent quarterly financial report, for the quarter ending Sep. 2017, Vertex Pharmaceuticals Incorporated (VRTX) delivered a 11.16% surprise with its net revenue. Sales reached $0.58 billion during the three-month period, compared to the average analyst estimate of $0.52 billion.

Meanwhile, during the same quarter Vertex Pharmaceuticals Incorporated (VRTX) delivered a 69.55% earnings surprise. Net earnings for the quarter were posted at $0.53 per share, whereas Wall Street had forecast $0.31 per share.

Ownership at Vertex Pharmaceuticals Incorporated (VRTX), According to Most Recent SEC Filings

A publicly-traded organization’s latest 13F filings tell us important details about its institutional ownership. Vertex Pharmaceuticals Incorporated (VRTX) has 0 billion shares outstanding currently, 94.16% of which belong to institutional investors. Those institutional holdings amount to $33.53 billion.

Additionally, according to the most recent 13F filing from Vertex Pharmaceuticals Incorporated (VRTX), there were 83 new positions totaling 1,831,519 shares of the company’s stock. There were 40 sold out positions, on the other hand, totaling 1,004,442 shares.

Short, Medium and Long Term Indicators

Assessing the average trade volume of a public company’s stock in the short, medium and long term is helpful to gain an understanding of trading activity and investor sentiment. Vertex Pharmaceuticals Incorporated (VRTX) has had a 20-day average volume of 1,305,065 shares, with an average of 100% of short term indicators pointed at Sell.

The stock’s 50-day average volume has been 1,564,172 shares, with an average of 100% of medium term indicators pointing toward Sell. Finally, its 100-day average volume is 1,743,986 shares with 100% of long-term indicators pointing to Sell.